Granules India Ltd (GRANULES) Q1FY26 Concall Summary - Jun-2025 Qtr
Performance Overview
- Granules India Ltd. (Granules) reported Q1 FY26 revenue of Rs.12,101 million, a 3% YoY growth and a 1% sequential increase. This includes Rs.291 million from the recent acquisition of Senn Chemicals AG.
- North America and Europe showed year-on-year and sequential growth, respectively. Rest of the World (ROW) sales declined due to PFI supply backlog from the Gagillapur facility.
- Gross margin improved significantly to 64.9%, a 593 basis point YoY increase and a 148 basis point sequential improvement, primarily due to the consolidation of Senn Chemicals AG.
- EBITDA was Rs.2,467 million (20.4% margin), a decline of 159 basis points YoY due to increased professional expenses for US FDA remediation efforts. Sequentially, EBITDA margin decreased by 69 basis points due to higher manpower costs from Senn Chemicals AG.
- Granules achieved several regulatory milestones, including successful FDA inspections at its US-based GPI site and API Unit I facility at Bonthapally, each with one observation. The new formulations facility at Genome Valley also cleared its first FDA pre-approval inspection with a single procedural observation.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.